Nektar TherapeuticsSan Carlos, CA, United States (NASDAQ (GS): NKTR)

Tools:

Buy A ReportBecome A Subscriber

Today's Special Offer

Nektar Therapeutics Financial Statements

Nektar Therapeutics Financial Information

Company Type Public
Headquarters
Fiscal Year-End December
Annual Report Company Web Site
Investor Relations Company Web Site
Edgar Online logo
This data is provided as per license from EDGAR Online

Nektar Therapeutics Income Statement

  2007 2006 2005
Revenue ($ mil.) 273.0 217.7 126.3
Gross Profit ($ mil.) 125.5 99.6 90.3
Operating Income ($ mil.) (36.2) (159.2) (182.6)
Total Net Income ($ mil.) (32.8) (154.8) (185.1)
Diluted EPS (Net Income) (0.36) (1.72) (2.15)
More Nektar Therapeutics financial information

Nektar Therapeutics Quarterly Statements

  Quarter Ending Sep 08 Quarter Ending Jun 08 Quarter Ending Mar 08
Revenue ($ mil.) 21.4 20.4 20.0
Gross Profit ($ mil.) 16.1 13.5 7.4
Operating Income ($ mil.) (34.6) (33.4) (41.9)
Total Net Income ($ mil.) (37.0) (33.4) (40.7)
Diluted EPS (Net Income) (0.40) (0.36) (0.44)
More Nektar Therapeutics financial information

Nektar Therapeutics Stock Quote & Chart

12/02/08 13:09:45 EST • NASDAQ • 4.58 • Decreased by -0.0950 • Decreased by -2.0343 %
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
Detailed QuoteInteractive Stock Chart

Nektar Therapeutics Financial Ratios

  Company Industry
Median		 Market
Median1
Price/Sales Ratio 2.71 2.00 0.83
Price/Earnings Ratio -- 9.32 9.28
Price/Book Ratio 3.18 1.50 0.80
Price/Cash Flow Ratio -- 7.89 5.25
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.

Detailed Nektar Therapeutics Financial Ratios

Nektar Therapeutics Competitive Intelligence

Alkermes Enzon MannKind
Annual Sales ($ mil.) 240.7 185.6 0.0
Employees -- 371 --
Market Cap ($ mil.) 726.1 171.5 336.7

Competitive Landscape